( ADZA) were among health care stocks' winners Monday, rising more than 50% on news of a merger.
( CYTC) agreed to acquire the maker of products for women's health for $24 a share, or $452 million. The merger is expected to close by the end of March. Shares of Adeza were up $8.25, or 53%, to $23.78 in recent trading. Cytyc shares were up 59 cents, or 2%, at $30.14.
was surging 91% Monday after the company said a trial of the liver cancer drug Nexavar
met its primary endpoint. Onyx and partner
( BAY) ended the phase III trial early on recommendation of an independent data-monitoring committee and gave all patients in the study access to Nexavar. Onyx shares were up $11.14 at $23.40 in recent trading.
dropped lower on reports that merger talks with
have come to an end. Bristol shares were recently down $1.05, or 3.7%, at $27.47, while Sanofi was higher by 24 cents, or 0.6%, at $44.02.
climbed higher on an 83% year-over-year increase in full-year revenue. The weight-loss company reported unaudited revenue of $73.5 million, up from $40.1 million in 2005 and higher than its previous guidance of $70 million to $72 million. Analysts are looking for $73.3 million in revenue, according to Thomson First Call. Shares were recently higher by $1.37, or 17.6%, at $9.14.
climbed higher on a fourth-quarter earnings beat of 9 cents a share. The provider of laser vision-correction services reported fourth-quarter earnings of $7.1 million, or 34 cents a share, on $58.8 million in sales. That compares with earnings of $6.6 million, or 30 cents a share, on $46.8 million in revenue in the prior-year period. Analysts were looking for EPS of 25 cents and revenue of $58.4 million.
For full-year 2006 LCA-Vision reported earnings of $38.3 million, or $1.80 a share, on $256.9 million in revenue. That compares with earnings of $31.7 million, or $1.47, on revenue of $192.4 million in 2005. Analysts were looking for full-year EPS of $1.71 on $256.5 million in revenue.
Looking forward, LCA-Vision expects earnings for full-year 2007 to be in the range of $2.05 to $2.15 a share with revenue growth between 20% and 25%. The stock was up $7.20, or 18.6%, at $45.91 in recent trading.
( NTMD) were climbing higher on news the company signed a worldwide licensing agreement with
for an extended-release formula of BiDil, the congestive heart failure medication for black patients. Shares of NitroMed were up 39 cents, or 11.2%, at $3.87. Elan was down 8 cents, or 0.6%, at $13.38.
( CHTT) shares were trading lower after the health care products company reported earnings that fell short of analysts' expectations. The company posted fiscal fourth-quarter earnings of $4.9 million, or 26 cents a share, on $65.1 million in revenue. Excluding items, EPS would have been 32 cents. That compares with earnings of $2.4 million, or 12 cents a share, on $63.9 million in the prior-year quarter. However, analysts were looking for EPS of 37 cents on $65.6 million in revenue.
For the full year, Chattem reported earnings of $45.1 million, or $2.34 a share, on $300.5 million in sales. Excluding items, EPS would have been $1.95. Analysts were looking for full-year EPS of $1.88 on $301 million in sales. In 2005, the company generated earnings of $36 million, or $1.77 a share, on $279.3 million in revenue.
Looking forward, the company expects EPS for fiscal 2007 to be in the range of $2.80 to $3.05, excluding compensation expenses. Shares of Chattem, which was downgraded by Brean Murray to sell from hold, were lower by $3.82, or 6.7%, at $53.60 in recent trading.